Oslo, Norway, 29 January 2026: Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announces that the first patient has been enrolled at one of the newly activated sites in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer. Read more…
Appointment builds on CHF 10 million seed financing and Board leadership expansion Basel, Switzerland, January 29, 2026 – TECregen, a biotechnology company pioneering thymus rejuvenation, today announced the appointment of Dr. Klaas P. Zuideveld, Ph.D., as Chief Executive Officer (CEO). Dr. Zuideveld will lead TECregen’s strategy and execution as the company advances its thymopoietic biologics designed to rejuvenate […]
Ready-to-use preformed antibiotic loaded spacers for hip, knee and shoulder revisions Choice of Charnley and Müller hip spacer designs, and left and right geometries for each knee Keele, UK, 29 January 2026 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft […]
Marketing executive brings 20+ years of global diabetes experience to support European scale-up and next-generation Kaleido launch readiness Utrecht, the Netherlands — January 29, 2026 ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, announced today that Reman McDonagh, PhD, has joined the Company as Vice President, Global Marketing. McDonagh’s appointment […]
28 January 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Read more…
